Lipid spheres as attractive nanoscale drug delivery platforms for cancer therapy

Journal of Nanomedicine and Nanotechnology

Volumn 3, Issue 1, 2012, Pages

  Yiv, Seang H ^a,b   Uckun, Fatih M ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cancer; Drug delivery; Formulation; Microemulsion; Nanomedicine; Oncology

Indexed keywords

EID: 84878050932     PISSN: None     EISSN: 21577439     Source Type: Journal    
DOI: 10.4172/2157-7439.1000128     Document Type: Review

References (55)

1. Jain RK, Stylianopoulos T (2010) Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 7: 653-664.
2. Torchilin VP (2007) Micellar nanocarriers: Pharmaceutical perspectives. Pharm Res 24: 1-16.
3. Nie S (2010) Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine 5: 523-528.
4. Lindman B, Alexandridis P (2000) Amphiphilic block copolymers: self-assembly and applications. Elsevier Science.
5. Davis ME, Chen ZG, Shin DM (2008) Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7: 771-782.
6. Petros RA, DeSimone JM (2010) Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Disco 9: 615-627.
7. Pouton CW, Wagstaff KM, Roth DM, Moseley GW, Jans DA (2007) Targeted delivery to the nucleus. Adv Drug Deliv Rev 59: 698-717.
8. Ferrari M (2005) Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5: 161-171.
9. Brewer E, Coleman J, Lowman A (2011) Emerging technologies of polymeric nanoparticles in cancer drug delivery. J Nanomaterials.
10. Guo S, Huang L (2011) Nanoparticles escaping RES and endosome: challenges for siRNA delivery for cancer therapy. J Nanomaterials.
11. Tiwari PM, Vig K, Dennis VA, Singh SR (2011) Functionalized gold nanoparticles and their biomedical applications. Nanomaterials 1: 31-63.
12. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, et al. (2008) Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 83: 761-769.
13. Bharali DJ, Khalil M, Gurbuz M, Simone TM, Mousa SA (2009) Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers. Int J Nanomedicine 4: 1-7.
14. Talegaonkar S, Azeem A, Ahmad FJ, Khar RK, Pathan SA, et al. (2008) Microemulsions: a novel approach to enhanced drug delivery. Recent Pat Drug Deliv Formul 2: 238-257.
15. Hoar TP, Schulman JH (1943) Transparent water-in-oil dispersions: the oleopathic hydro-micelle. Nature 152: 102-103.
16. Schulman JH, Stoeckenius H, Prince LM (1959) Mechanism of formation and structure of microemulsions by electron microscopy. J Phys Chem 63: 1677-1680.
17. Aniansson EAG, Wall SN (1974) Kinetics of step-wise micelle association. J Phys Chem 78: 1024-1030.
18. Zana R (2005) Dynamics of Surfactant Self-Assemblies: Micelles, Microemulsions, Vesicles and Lyotropic Phases. CRC Press.
19. Savić R, Luo L, Eisenberg A, Maysinger D (2003) Micellar nanocontainers distribute to defined cytoplasmic organelles. Science 300: 615-618.
20. Pounder RJ, Willcock H, Ieong NS, OReilly RK, Dove AP (2011) Stereocomplexation in novel degradable amphiphilic block copolymer micelles of poly(ethylene oxide) and poly(benzyl a-malate). RSC Soft Matter 7: 10987-10993.
21. Kwon GS, Forrest ML (2006) Amphiphilic block copolymer micelles for nanoscale drug delivery. Drug Development Research 67: 15-22.
22. Mikhail AS, Allen C (2009) Block copolymer micelles for delivery of cancer therapy: Transport at the whole body, tissue and cellular levels. J Control Release 138: 214-223.
23. Gao ZG, Fain HD, Rapoport N (2005) Controlled and targeted tumor chemotherapy by micellar-encapsulated drug and ultrasound. J Control Release 102: 203-222.
24. Licciardi M, Giammona G, Du J, Armes SP, Tang Y, et al. (2006) New folatefunctionalized biocompatible block copolymer micelles as potential anti-cancer drug delivery systems. Polymer 47: 2946-2955.
25. Nishyama N, Kataoka K (2003) Polymeric micelle drug carrier systems: PEGPAsp (Dox) and second generation of micellar drugs. Polymer Drugs in the Clinical Stage 519: 155-177.
26. Kabanov AV, Batrakova EV, Alakhov VY (2002) Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev 54: 759-779.
27. Kim DW, Kim SY, Kim HK, Kim SW, Shin SW, et al. (2007) Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 18: 2009-2014.
28. Kim J, Shin S (2010) Cost-effectiveness of Genexol-PM for treating metastatic breast cancer. J Breast Cancer 13: 104-110.
29. Lee SW, Yun MH, Jeong SW, In CH, Kim JY, et al. (2011) Development of docetaxel-loaded intravenous formulation, Nanoxel-PM™ using polymerbased delivery system. J Control Release 155: 262-71.
30. Matsumura Y, Hamaguchi T, Ura T, Muro K, Yamada Y, et al. (2004) Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer 91: 1775-1781.
31. Hamaguchi T, Kato K, Yasui H, Morizane C, Ikeda M, et al. (2007) A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br J Cancer 97: 170-176.
32. Narang AS, Varia S (2011) Role of tumor vascular architecture in drug delivery. Adv Drug Deliv Rev 63: 640-658.
33. Heyes ME, Bourrel MU, El-Emary MM, Schechter RS, Wade WH (1979) Interfacial tension and behavior of nonionic surfactants. SPE Journal 19: 349-356.
34. Abe M, Schechter D, Schechter RS, Wade WH, Weerasooriya U, et al. (1986) Microemulsion formation with branched tail polyoxyethylene sulfonate surfactants. J Colloid Interface Sci 114: 342-356.
35. Cayias JL, Schechter RS, wade WH (1975) The Measurement of Low Interfacial Tension via the Spinning Drop Technique. Adsorption at Interfaces 8: 234-237.
36. DeGennes PG, Taupin C (1982) Microemulsions and the flexibility of oil/water interfaces. J Phys Chem 86: 2294-2304.
37. Talmon Y, Prager S (1978) Statistical thermodynamics of phase equilibria in microemulsions. J Chern Phys 69: 2984-2991.
38. Nagarajan R, Ruckenstein E (2000) Molecular theory of microemulsions. Langmuir 16: 6400-6415.
39. Yiv SH, Tustian AK (2001) Drug delivery compositions suitable for intravenous injection, United States Patent 6,245,349 B1.
40. Zaloga GP, Dunham AJ, Gonyon TM, Best LM (2007) Safety and stability of lipid emulsions. Nutr Clin Pract 22: 367-369.
41. Rey JB, Faure C, Brion F (2005) Stability of all-in-one standard formulae for paediatric parenteral nutrition. PDA J Pharm Sci Tech 59: 206-220.
42. Mehta RC, Head LF, Hazrati AM, Parr M, Rapp RP, et al. (1992) Fat emulsion particle-size distribution in total nutrient admixtures. Am J Hosp Pharm 49: 2749-2755.
43. Deitel M, Friedman KL, Cunnane S, Lea PJ, Chaiet A, et al. (1992) Emulsion stability in a total nutrient admixture for total parenteral nutrition. J Am Coll Nutr 11: 5-10.
44. Strickley RG (2004) Solubilizing excipients in oral and injectable formulations. Pharm Res 21: 201-230.
45. Skubitz KM (2002) Phase II trial of pegylated-liposomal doxorubicin (doxil) in mesothelioma. Cancer Invest 20: 693-699.
46. Wang Y, Wu KC, Zhao BX, Zhao X, Wang X, et al. (2011) A novel paclitaxel microemulsion containing a reduced amount of cremophor el: pharmacokinetics, biodistribution, and in vivo antitumor efficacy and safety. J Biomed Biotechnol.
47. Ryoo HK, Park CW, Chi SC, Park ES (2005) Development of propofol loaded microemulsion systems for parenteral delivery. Arch Pharm Res 28: 1400-140.
48. Park KM, Kim CK (1999) Preparation and evaluation of flurbiprofen-loaded microemulsion for parenteral delivery. Int J Pharm 181: 173-179.
49. Date AA, Nagarsenker MS (2008) Design and evaluation of microemulsions for improved parenteral delivery of propofol. AAPS PharmSciTech 9: 138-145.
50. Dubey PK, Kumar A (2005) Pain on injection of lipid-free propofol and propofol emulsion containing medium-chain triglyceride: a comparative study. Anesth Analg 101: 1060-1062.
51. Lee JM, Park KM, Lim SJ, Lee MK, Kim CK (2002) Microemulsion formulation of clonixic acid: solubility enhancement and pain reduction. J Pharm Pharmacol 54: 43-49.
52. Wang J, Maitani Y, Takayama K (2002) Antitumor effects and pharmacokinetics of aclacinomycin A carried by injectable emulsions composed of vitamin E, cholesterol, and PEG-lipid. J Pharm Sci 91: 1128-1134.
53. Junping W, Takayama K, Nagai T, Maitani Y (2003) Pharmacokinetics and antitumor effects of vincristine carried by microemulsions composed of PEGlipid, oleic acid, vitamin E and cholesterol. Int J Pharm 251: 13-21.
54. Wang JP, Wang W, Zhao LN (2009) Paclitaxel carried by long circulating microemulsions used for metronomic chemotherapy of cancer. Yao Xue Xue Bao 44: 911-914.
55. Shiokawa T, Hattori Y, Kawano K, Ohguchi Y, Kawakami H, et al. (2005) Effect of polyethylene glycol linker chain length of folate-linked microemulsions loading aclacinomycin a on targeting ability and antitumor effect in vitro and in vivo. Clin Cancer Res 11: 2018-2025.